

1. [GST may help pharma industry regain lost share](#) – **The Times of India**

The roll out of Goods and Services Tax (GST) will help Gujarat regain its lost share in pharma production. With tax structure getting uniform across India many companies which had shifted to states such as Himachal Pradesh, Sikkim and Assam to avail tax incentives are likely to shift back to Gujarat for future expansion.

However, industry players are still uncertain about the continuance of tax incentives in North East states post GST implementation. In fact, IDMA has planned a separate seminar on GST's impact on pharma industry during its upcoming Pharmac India exhibition. The event will be held in Ahmedabad in October.

1. [GST may help pharma industry regain lost share](#) – The Times of India
2. [Many Indian Drug Cos Face Scrutiny in US Price Hike Probe](#) – The Economic Times
3. [Pharma department bats for change in Drugs & Cosmetics Act](#) – Mint
4. [Grim diagnosis for pharma firms haunted by price bogey](#) – Business Standard
5. [Regulators step up scrutiny of drug makers](#) – Business Standard
6. [Proactive selling, sparse info: State medical council hot on IVF clinics' heels](#) – The Times of India
7. [Why 1.1 mn HIV+ve Indians don't get drugs they need](#) – Business Standard
8. [Dr Reddy's in Dow Jones Sustainability Indices](#) – The Hindu Business Line
9. [Fosun Pharma looks to digest India's Gland, eyes other markets](#) – Reuters.com
10. [Indian pharma market registers strong growth of 15.3% in August 2016](#) – Pharmabiz.com

2. [Many Indian Drug Cos Face Scrutiny in US Price Hike Probe](#) – **The Economic Times**

Indian drugmakers, which thrived due to the booming generics market in the US, may be exposed to a risk of an uncertain future, as the uproar over rising prices of life-saving medicines gathers pace and threatens to spill over from innovators of medicines to makers of generic drugs. A probe kicked off last week by the US Department of Justice (DOJ) against Sun Pharma's subsidiary Taro seeking documents related to pricing of generic products is on expected lines, according to senior market analysts, who said the investigations may broaden to a few other large Indian drugmakers.

(Online link unavailable at the moment, please refer to the epaper link)

3. [Pharma department bats for change in Drugs & Cosmetics Act](#) – **Mint**

The Department of Pharmaceuticals, under the ministry of chemicals and fertilizers, has suggested modifications to the Drugs & Cosmetics Act to legally allow pharmacists of Jan Aushadhi stores to offer alternate generic drugs to customers instead of prescribed branded drugs, an official from the pharmaceutical department said on the condition of anonymity. The move comes in the wake of the government having targeted opening 3,000 Jan Aushadhi stores in the current financial year, as announced by finance minister Arun Jaitley in his budget speech. The Jan Aushadhi scheme, started in 2008, aims to provide affordable and quality medicines to the poor and disadvantaged through increased focus on unbranded generic medicines.

4. [Grim diagnosis for pharma firms haunted by price bogey](#) – Business Standard

Several pharmaceutical companies are likely to see a blast from the past, with the department of pharmaceuticals (DoP) having directed the National Pharmaceutical Pricing Authority (NPPA) to dig up old cases of overpriced drugs. The DoP wants a list of pharma companies that magnified drug prices from the year 1979 to 1986. At least Rs 300 crore would be the sum the government had slapped on these companies due to overcharging. This amount was meant to go into the Drug Price Equalisation Account. The latest demand from the DoP comes at a time when the pharmaceutical industry and the NPPA are at loggerheads over pricing issues.

5. [Regulators step up scrutiny of drug makers](#) – Business Standard

Britain's drug regulator last month revoked its good manufacturing practice certificate for Pfizer's Chennai plant and put out an alert on products made there. This points out to continued quality lapses by pharmaceutical units in the country despite an industry-wide effort to clean up the rot. Between 2011 and 2016, 27 drug manufacturing plants in India received warning letters from the US Food and Drug Administration (FDA) for data integrity violations and 15 of them had import alerts issued against them, according to a Nomura Research report. None of the alerts has been withdrawn, resulting in delayed product approvals or restrictions in export to the world's largest pharmaceuticals market.

6. [Proactive selling, sparse info: State medical council hot on IVF clinics' heels](#) – The Times of India

A city-based fertility centre had to be warned thrice before its proprietor finally removed a banner showing his face, spanning six floors. Another doctor was hauled up after a dozen pictures of his beamed at various points in the airport, promising 'healthy, perfect babies.' A group of junior gynecologists was pulled up for paying an online advertising agency to rank them the best in the field of reproductive medicine. From promising 95% success rate to giving 100% money-back guarantee aggressive marketing with misleading claims and sparse information seem to be the mantra for most IVF clinics, bringing them under the state medical council scanner for ethical violations.

7. [Why 1.1 mn HIV+ve Indians don't get drugs they need](#) – Business Standard

Each of an estimated 2.1 million Indians infected with the human immunodeficiency virus (HIV) should be getting a cocktail of drugs to prolong their lives and reduce infections, but no more than 44 per cent do, the Minister of Health told the Lok Sabha in April 2016. In India, the drug cocktail is given to patients with a count of less than 350 CD4 cells per mm³ of blood -- CD4 cells are white blood cells, a count of which indicates the health of a person's immune system.

8. [Dr Reddy's in Dow Jones Sustainability Indices](#) – The Hindu Business Line

Dr Reddy's Laboratories has been listed as an Index component of the Dow Jones Sustainability Indices (DJSI) 2016 in the pharmaceuticals, biotechnology and life sciences industry group. The Hyderabad-based company has been recognised for its corporate sustainability leadership. The listing was based on 22 criteria, with Dr Reddy's receiving high scores for product quality and recall management, codes of business conduct, environmental reporting, corporate citizenship and philanthropy.

Also reported by-

- [Dr Reddy's enters Dow Jones Indices](#) – Business Standard
- [Dr Reddy's listed on Dow Jones Sustainability Indices](#) – The Hindu
- [Dr Reddy's listed on Dow Jones Sustainability Indices 2016](#) – The Economic Times
- [Dr Reddy's listed on Dow Jones Sustainability Indices](#) – The Financial Express

9. [Fosun Pharma looks to digest India's Gland, eyes other markets](#) – Reuters.com

Chinese drugmaker Shanghai Fosun Pharmaceutical Group Co Ltd ([600196.SS](#)) already has one eye on investments in other overseas markets after it announced a nearly \$1.3 billion deal in July to India's Gland Pharma, the firm's chairman said on Tuesday. Fosun Pharma's chairman Chen

Qiyu said the firm was focused on integrating the Indian injectible medicine maker with Fosun's current business to help tap markets in Europe and the United States as well as within India itself.

10. [Indian pharma market registers strong growth of 15.3% in August 2016](#) – Pharmabiz.com

The Indian pharmaceutical market (IPM) has registered a strong growth of 15.3 per cent to Rs. 9,643 crore during August 2016 as against 13.2 per cent in the August 2015. It also clocked the highest incremental value over last year to Rs. 1,278 crore. Average growth for the quarter worked out to 8.1 per cent against 12.9 per cent during last year. The incremental value added in August is 55 per cent of the combined value of April-July 16. According to AIOCD Pharmsofttech AWACS report, market also crossed the Rs. 9,000 crore mark continuously for the last 2 months and gastro intestinal markets cross Rs. 12,000 crore on MAT basis. Market has added Rs. 1,278 crore over last year, whereas last year the market had added up Rs. 977 crore. For the month of August the GDs 9.1 per cent in volumes, 2.9 per cent in price increases & 3.3 per cent in NIs. August quarter saw a volume growth of 4.0 per cent & price growth the lowest in last 6 quarters at 3.8 per cent.